Loading organizations...
Loading organizations...
Key people at Charles River Laboratories.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Jan 1, 2025 | Deciphex | $32.0M Series C | Inga Deakin | Act Venture Capital, Amino Collective, Hummingbird Ventures, MizMaa Ventures, Molten Ventures, Not Boring Capital, Seroba Life Sciences, HBAN Medtech Syndicate, Irrus Investments, Nextsteps Capital |
| Jun 1, 2023 | Vernal Biosciences | $20.0M Series A | David Q. Anderson, Charles River Laboratories | Dynamk Capital, Vermont Center for Emerging Technologies |
| Jan 26, 2023 | iVexSol | $23.8M Series A | — | Asahi Kasei Medical, BioLife Solutions, Bristol Myers Squibb, Casdin Capital |
| Jun 1, 2022 | Vernal Biosciences | $21.0M Series A | Dynamk Capital, David Q. Anderson | Errik Anderson, ATUM |
| May 1, 2022 | Deciphex | $12.0M Series B | Act Venture Capital | Molten Ventures, Seroba Life Sciences, HBAN Medtech Syndicate, Irrus Investments, Nextsteps Capital, Novartis |
| Nov 1, 2021 | bit.bio | $100.0M Series B | — | BDC Venture Capital, BoxOne Ventures, SVG Ventures-THRIVE, W Fund, ARCH Venture Partners, Foresite Capital, Metaplanet, National Resilience, Tencent |